quinazolines has been researched along with rvx 208 in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McNeill, E | 1 |
| Bailey, D; Campbell, S; Chatur, S; Chiacchia, FS; Genest, J; Gordon, A; Hafiane, A; Hansen, HC; Jahagirdar, R; Johansson, J; Krimbou, L; Wagner, GS; Wong, NC | 1 |
| Inazu, A | 1 |
| Davidson, MH | 1 |
| Ballantyne, CM; Borgman, M; Gordon, A; Johansson, J; Kastelein, JJ; Nicholls, SJ; Nissen, SE; Taylor, A; Wolski, K | 1 |
| Shah, PK | 1 |
| Ballantyne, CM; Barter, PJ; Borgman, MR; Brewer, HB; Gordon, A; Johannson, J; Kastelein, JJ; Nicholls, SJ; Nissen, SE; Wong, NC | 1 |
| Joy, TR | 1 |
| Boudjabi, S; Cotterill, IC; Hansen, HC; Khlebnikov, V; Khmelnitsky, YL; Madhava Reddy, M; Michels, PC; Mozhaev, VV; Wagner, GS | 1 |
| Bountra, C; Brennan, PE; Brotherton, D; Diez-Dacal, B; Fedorov, O; Felletar, I; Filippakopoulos, P; Knapp, S; Lingard, H; Martin, S; Müller, S; Philpott, M; Picaud, S; Savitsky, P; Wells, C | 1 |
| Attwell, S; Campeau, E; Fontano, E; Gesner, EM; Hansen, HC; Kharenko, OA; McLure, KG; Stein, A; Suto, RK; Tsujikawa, L; Wagner, GS; Wasiak, S; White, A; Wong, NC; Young, PR | 1 |
| Günther, S; Lucas, X | 1 |
| Papavassiliou, AG; Papavassiliou, KA | 1 |
| Attwell, S; Azhar, S; Hansen, HC; Jahagirdar, R; Johansson, J; McLure, KG; Srivastava, RA; Tobin, J; Wagner, GS; Wong, NC; Wu, J; Young, PR; Yu, R; Zhang, H | 1 |
| Chinetti-Gbaguidi, G; Colin, S; Kuivenhoven, JA; Staels, B | 1 |
| Banach, M; Mikhailidis, DP; Nikolic, D; Rizzo, M; Wong, NC | 1 |
| Ballantyne, CM; Barter, PJ; Borgman, M; Brewer, HB; Herrman, JP; Hu, B; Kastelein, JJ; Kataoka, Y; Merkely, B; Nicholls, SJ; Nissen, SE; Puri, R; Uno, K; Wolski, K | 1 |
| Davis, J; Gadkar, K; Lu, J; Mazer, NA; Ramanujan, S; Sahasranaman, S | 1 |
| Gilham, D; Gordon, A; Halliday, C; Johansson, J; Kulikowski, E; McLure, K; Norek, K; Patel, RG; Sweeney, M; Tsujikawa, LM; Wasiak, S; Wong, NC; Young, P | 1 |
| Barter, P; Carey, AL; Cobelli, C; Dalla-Man, C; Duffy, SJ; Formosa, MF; Gordon, A; Huynh, K; Johansson, J; Khan, AA; Kingwell, BA; Meikle, PJ; Mundra, PA; Natoli, AK; Otvos, JD; Reddy-Luthmoodoo, M; Rye, KA; Siebel, AL; Sviridov, D; Trinh, SK; van Hall, G; Wong, NC | 1 |
| Banerjee, K; Bhadra, R; Ghosh, GC; Ghosh, RK; Gupta, A | 1 |
| Calosing, C; Gilham, D; Halliday, C; Jahagirdar, R; Johansson, J; Kulikowski, E; Sweeney, M; Tsujikawa, LM; Wasiak, S; Wong, NC | 1 |
7 review(s) available for quinazolines and rvx 208
| Article | Year |
|---|---|
RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases.
Topics: Animals; Apolipoprotein A-I; Cardiovascular Diseases; Clinical Trials as Topic; Gene Expression; Humans; Quinazolines; Quinazolinones | 2010 |
[Novel therapy for atherosclerosis and inflammatory vascular disease].
Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Design; Esters; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oxazolidinones; Oximes; Probucol; Quinazolines; Quinazolinones; Sulfhydryl Compounds | 2011 |
Rvx 208.
Topics: Acute Coronary Syndrome; Alzheimer Disease; Animals; Atherosclerosis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Quinazolines; Quinazolinones | 2011 |
Novel HDL-based therapeutic agents.
Topics: Animals; Apolipoprotein A-I; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Hypolipidemic Agents; Molecular Mimicry; Quinazolines; Quinazolinones; Treatment Outcome | 2012 |
Emerging small molecule drugs.
Topics: Animals; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Design; Dyslipidemias; Humans; Hypolipidemic Agents; Liver X Receptors; Molecular Targeted Therapy; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Quinazolines; Quinazolinones; Signal Transduction | 2015 |
An evaluation of RVX-208 for the treatment of atherosclerosis.
Topics: Animals; Atherosclerosis; Cholesterol, HDL; Epigenesis, Genetic; Humans; Metabolic Diseases; Plaque, Atherosclerotic; Quinazolines; Quinazolinones | 2015 |
RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond.
Topics: Apolipoprotein A-I; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lipoproteins, HDL; Protein Synthesis Inhibitors; Proteins; Quinazolines; Quinazolinones | 2017 |
5 trial(s) available for quinazolines and rvx 208
| Article | Year |
|---|---|
RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.
Topics: Animals; Apolipoprotein A-I; Cells, Cultured; Chlorocebus aethiops; Cholesterol, HDL; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hep G2 Cells; Humans; In Vitro Techniques; Macaca fascicularis; Male; Molecular Weight; Probability; Quinazolines; Quinazolinones; Random Allocation; Risk Assessment | 2010 |
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prospective Studies; Quinazolines; Quinazolinones; Treatment Outcome | 2011 |
ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.
Topics: Adolescent; Apolipoprotein A-I; Cardiotonic Agents; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Humans; Male; Plaque, Atherosclerotic; Quinazolines; Quinazolinones; Ultrasonography | 2012 |
Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Quinazolines; Quinazolinones | 2016 |
Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial.
Topics: Aged; Apolipoprotein A-I; Blood Glucose; Carbohydrate Metabolism; Cholesterol, HDL; Cross-Over Studies; Double-Blind Method; Humans; Lipoproteins; Lipoproteins, HDL; Male; Middle Aged; Prediabetic State; Quinazolines; Quinazolinones | 2016 |
11 other study(ies) available for quinazolines and rvx 208
| Article | Year |
|---|---|
Apolipoprotein A-I therapy promise, challenges, and disappointment.
Topics: Apolipoprotein A-I; Cholesterol, HDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Quinazolines; Quinazolinones; Treatment Outcome | 2011 |
Atherosclerosis: targeting endogenous apo A-I--a new approach for raising HDL.
Topics: Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Quinazolines; Quinazolinones; Risk Factors | 2011 |
In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208).
Topics: Animals; Humans; Microsomes, Liver; Molecular Structure; Quinazolines; Quinazolinones; Rabbits | 2013 |
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Topics: Crystallization; Fluorescence Recovery After Photobleaching; Hep G2 Cells; Humans; Models, Molecular; Molecular Structure; Oligonucleotide Array Sequence Analysis; Protein Binding; Protein Structure, Tertiary; Quinazolines; Quinazolinones; Transcription Factors | 2013 |
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Binding Sites; Cell Cycle Proteins; Cell Line; Crystallography, X-Ray; Epigenesis, Genetic; Hepatocytes; Humans; Models, Molecular; Nuclear Proteins; Protein Conformation; Protein Serine-Threonine Kinases; Quinazolines; Quinazolinones; Recombinant Proteins; RNA, Small Interfering; Transcription Factors | 2013 |
Targeting the BET family for the treatment of leukemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Azepines; Benzodiazepines; Cell Cycle Proteins; Cell Proliferation; Gene Expression; Humans; Leukemia; Nuclear Proteins; Protein Serine-Threonine Kinases; Quinazolines; Quinazolinones; RNA-Binding Proteins; Transcription Factors; Triazoles | 2014 |
Bromodomains: pockets with therapeutic potential.
Topics: Benzodiazepines; Binding Sites; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Protein Binding; Protein Interaction Domains and Motifs; Quinazolines; Quinazolinones; Small Molecule Libraries | 2014 |
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
Topics: Animals; Aorta; Aortic Diseases; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; Betaine-Homocysteine S-Methyltransferase; Cell Line; Cholesterol, HDL; Cholesterol, LDL; Cytokines; Diet, Fat-Restricted; Diet, Western; Drug Evaluation, Preclinical; Endothelial Cells; Gene Expression Profiling; Humans; Hyperlipidemias; Inflammation; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinazolines; Quinazolinones; RNA, Messenger; U937 Cells | 2014 |
Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.
Topics: Apolipoprotein A-I; Biological Transport; Biomarkers; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Models, Biological; Quinazolines; Quinazolinones; Risk Factors; Up-Regulation | 2016 |
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
Topics: Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cells, Cultured; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Gene Expression Profiling; Hepatocytes; Humans; Hypolipidemic Agents; Liver; Male; Oligonucleotide Array Sequence Analysis; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Retrospective Studies; Signal Transduction; Time Factors; Up-Regulation | 2016 |
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).
Topics: Animals; Cardiovascular Diseases; Cells, Cultured; Complement Activation; Complement Inactivating Agents; Complement System Proteins; Cytokines; Gene Expression Profiling; Hepatocytes; Humans; Immunity, Innate; Mice, SCID; Primary Cell Culture; Proteins; Proteomics; Quinazolines; Quinazolinones; Signal Transduction | 2017 |